Finnish biomedical start-up Nightingale Health obtains CE mark for blood analysis platform
Finnish biomedical startup Nightingale Health Ltd announced today CE marking for its blood biomarker analysis platform. The CE mark enables the clinical use of the analysis service and the analysed measures of creatinine and glucose in the EU region.Nightingale’s goal is to bring dozens of biomarkers included in the analysis platform gradually available for clinical use within the next year. The obtained CE mark is a remarkable step towards the company’s aim, enabling better prediction and targeted care for chronic diseases. Nightingale Health's blood biomarker analysis platform is